Drugs / B9
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06446830 | May 2024 → Nov 2025 overdue | — | Ain Shams University | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03887169 Background | Sep 2019 → Jun 2020 | inborn mitochondrial metabolism disorder, pulmonary alveolar proteinosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06446830 ↗ |
| Route | Oral | “oral vitamin B complex tablets preoperative and continue post-operative for 2 days” NCT06446830 ↗ |